PMID- 26970668
OWN - NLM
STAT- MEDLINE
DCOM- 20170126
LR  - 20190219
IS  - 1557-9816 (Electronic)
IS  - 0955-470X (Print)
IS  - 0955-470X (Linking)
VI  - 30
IP  - 2
DP  - 2016 Apr
TI  - Modulation of human allogeneic and syngeneic pluripotent stem cells and 
      immunological implications for transplantation.
PG  - 61-70
LID - S0955-470X(15)30022-7 [pii]
LID - 10.1016/j.trre.2016.02.001 [doi]
AB  - Tissues derived from induced pluripotent stem cells (iPSCs) are a promising 
      source of cells for building various regenerative medicine therapies; from simply 
      transplanting cells to reseeding decellularized organs to reconstructing 
      multicellular tissues. Although reprogramming strategies for producing iPSCs have 
      improved, the clinical use of iPSCs is limited by the presence of unique human 
      leukocyte antigen (HLA) genes, the main immunologic barrier to transplantation. 
      In order to overcome the immunological hurdles associated with allogeneic tissues 
      and organs, the generation of patient-histocompatible iPSCs (autologous or 
      HLA-matched cells) provides an attractive platform for personalized medicine. 
      However, concerns have been raised as to the fitness, safety and immunogenicity 
      of iPSC derivatives because of variable differentiation potential of different 
      lines and the identification of genetic and epigenetic aberrations that can occur 
      during the reprogramming process. In addition, significant cost and regulatory 
      barriers may deter commercialization of patient specific therapies in the 
      short-term. Nonetheless, recent studies provide some evidence of immunological 
      benefit for using autologous iPSCs. Yet, more studies are needed to evaluate the 
      immunogenicity of various autologous and allogeneic human iPSC-derived cell types 
      as well as test various methods to abrogate rejection. Here, we present 
      perspectives of using allogeneic vs. autologous iPSCs for transplantation 
      therapies and the advantages and disadvantages of each related to differentiation 
      potential, immunogenicity, genetic stability and tumorigenicity. We also review 
      the current literature on the immunogenicity of syngeneic iPSCs and discuss 
      evidence that questions the feasibility of HLA-matched iPSC banks. Finally, we 
      will discuss emerging methods of abrogating or reducing host immune responses to 
      PSC derivatives.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Sackett, S D
AU  - Sackett SD
AD  - Division of Transplantation, Department of Surgery, University of 
      Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
FAU - Brown, M E
AU  - Brown ME
AD  - Division of Transplantation, Department of Surgery, University of 
      Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
FAU - Tremmel, D M
AU  - Tremmel DM
AD  - Division of Transplantation, Department of Surgery, University of 
      Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
FAU - Ellis, T
AU  - Ellis T
AD  - Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison 
      School of Medicine and Public Health, Madison, WI, USA.
FAU - Burlingham, W J
AU  - Burlingham WJ
AD  - Division of Transplantation, Department of Surgery, University of 
      Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
FAU - Odorico, J S
AU  - Odorico JS
AD  - Division of Transplantation, Department of Surgery, University of 
      Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA. 
      Electronic address: jon@surgery.wisc.edu.
LA  - eng
GR  - TL1TR000429/TR/NCATS NIH HHS/United States
GR  - UL1 TR000427/TR/NCATS NIH HHS/United States
GR  - T32 GM007215/GM/NIGMS NIH HHS/United States
GR  - R01-AI066219/AI/NIAID NIH HHS/United States
GR  - TL1 TR000429/TR/NCATS NIH HHS/United States
GR  - R01 AI066219/AI/NIAID NIH HHS/United States
GR  - UL1TR000427/TR/NCATS NIH HHS/United States
GR  - T32 AI125231/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160210
PL  - United States
TA  - Transplant Rev (Orlando)
JT  - Transplantation reviews (Orlando, Fla.)
JID - 8804364
SB  - IM
MH  - Cell Differentiation
MH  - Humans
MH  - Immunity, Cellular/*immunology
MH  - Induced Pluripotent Stem Cells/*cytology/immunology
MH  - *Stem Cell Transplantation
PMC - PMC4859756
MID - NIHMS768239
EDAT- 2016/03/14 06:00
MHDA- 2017/01/27 06:00
PMCR- 2017/04/01
CRDT- 2016/03/14 06:00
PHST- 2015/11/09 00:00 [received]
PHST- 2016/02/05 00:00 [accepted]
PHST- 2016/03/14 06:00 [entrez]
PHST- 2016/03/14 06:00 [pubmed]
PHST- 2017/01/27 06:00 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - S0955-470X(15)30022-7 [pii]
AID - 10.1016/j.trre.2016.02.001 [doi]
PST - ppublish
SO  - Transplant Rev (Orlando). 2016 Apr;30(2):61-70. doi: 10.1016/j.trre.2016.02.001. 
      Epub 2016 Feb 10.